| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1468-1331.2006.01439.X |
| P698 | PubMed publication ID | 16417592 |
| P2093 | author name string | M Hallett | |
| D Dressler | |||
| P2860 | cites work | Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery | Q34282549 |
| Treatment of blepharospasm with botulinum toxin. A preliminary report | Q39552868 | ||
| Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 | ||
| P921 | main subject | botulinum toxin type A | Q4095199 |
| immunology | Q101929 | ||
| P304 | page(s) | 11-15 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc | |
| P478 | volume | 13 Suppl 1 |
| Q51540843 | A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. |
| Q35681898 | A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins |
| Q37987557 | Advances in the use of botulinum neurotoxins in facial esthetics |
| Q39446871 | Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity |
| Q33771420 | Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies |
| Q36828130 | Botulinum neurotoxin type A in facial aesthetics |
| Q37117645 | Botulinum toxin drugs: future developments |
| Q37641993 | Botulinum toxin type A for upper limb spasticity after stroke |
| Q26824771 | Clinical relevance of botulinum toxin immunogenicity |
| Q92382312 | Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia |
| Q36511584 | Clinical use of non-A botulinum toxins: botulinum toxin type B. |
| Q92923002 | Comments on Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491 |
| Q33881470 | Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats |
| Q51016593 | Effect of botulinum neurotoxin treatment in the lateral spread monitoring of microvascular decompression for hemifacial spasm. |
| Q37987484 | Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. |
| Q26859917 | Emerging opportunities for serotypes of botulinum neurotoxins |
| Q47965734 | Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs |
| Q39348345 | First experiences in deep brain stimulation for cervical dystonia |
| Q36844148 | Future aspects of botulinum neurotoxins |
| Q92583622 | High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment |
| Q31114675 | High doses of botulinum toxin, from efficacy to safety: experimental data |
| Q45949242 | Iatrogenic botulism in a child with spastic quadriparesis. |
| Q92905829 | Immunogenicity Associated with Botulinum Toxin Treatment |
| Q38046142 | Immunogenicity of botulinum toxins |
| Q39010241 | Immunological aspects of botulinum toxin therapy |
| Q50862349 | Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm. |
| Q37312931 | Influence of injection of Chinese botulinum toxin type A on the histomorphology and myosin heavy chain composition of rat gastrocnemius muscles |
| Q48744935 | Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury |
| Q38120775 | Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm |
| Q37579142 | Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children |
| Q42086848 | Neurologic uses of botulinum neurotoxin type A. |
| Q38607345 | Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis |
| Q36317697 | None detectable retrograde transport of Chinese botulinum toxin type A in mice by single intramuscular injection |
| Q48034806 | Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity |
| Q45250923 | Prolonged vastus lateralis denervation after botulinum toxin type A injection |
| Q91994510 | Rapid Detection of Botulinum Neurotoxins-A Review |
| Q28304077 | Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction |
| Q59153415 | Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story |
| Q37811268 | Review and Update of Involuntary Facial Movement Disorders Presenting in the Ophthalmological Setting |
| Q38457792 | RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study |
| Q33696600 | Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review |
| Q36656478 | Safety and efficacy of botulinum toxin type A following long-term use. |
| Q37457570 | Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials |
| Q33740588 | Temporal characteristics of botulinum neurotoxin therapy |
| Q26851170 | Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review |
| Q37717924 | Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis |
| Q83298968 | [Botulinum toxin in nonneurogenic bladder dysfunction] |
| Q79846509 | [Current outlook on botulinum toxin medications] |
| Q94947259 | [Cutaneous immune system] |
| Q84168227 | [Long-term effects of botulinum toxin treatment] |
| Q55042153 | [Pharmacological aspects of therapeutic botulinum toxin preparations]. |
Search more.